Phase 3 Randomized Double-Blind Multicenter Study of Sonrotoclax Plus Zanubrutinib Versus Placebo Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma
Trial Description
The goal of this study is to compare how well sonrotoclax plus zanubrutinib works versus
zanubrutinib plus placebo in treating adults with relapsed/refractory (R/R) mantle cell
lymphoma (MCL). This study will also look at the safety of sonrotoclax plus zanubrutinib
versus zanubrutinib plus placebo.
Eligibility Requirements
Inclusion Criteria:
- Histologically locally confirmed diagnosis of MCL based on the World Health
Organization 2022 classification of Haematolymphoid Tumors (WHO-HAEM5), or based on
International Consensus Classification (ICC)
- Ability to provide archival or fresh tumor tissue for retrospective central
confirmation of MCL diagnosis
- Received 1 to 5 prior lines of systemic therapy including an anti-CD20 monoclonal
antibody (mAb)-based immunotherapy or chemoimmunotherapy and requiring treatment in
the opinion of the investigator
- Relapsed or refractory disease after the last line of therapy
- Measurable disease defined as ≥ 1 nodal lesion that is > 1.5 cm in longest diameter,
or ≥ 1 extranodal lesion that is > 1 cm in longest diameter
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2
- Adequate organ function
Exclusion Criteria:
- Prior therapy with B-cell lymphoma-2 inhibitor (BCL2i)
- Prior therapy with BTK degraders
- Prior therapy with covalent or non-covalent Bruton tyrosine kinase inhibitor (BTKi)
unless the participant was intolerant of non-zanubrutinib covalent or non-covalent
BTKi. Participants with refractory disease to BTKi therapy or relapse attributed to
failure of BTKi therapy are ineligible.
- Prior autologous stem cell transplantation or chimeric antigen receptor T-cell
therapy within 3 months before first dose of study drug
- Prior allogeneic stem cell transplant within 6 months of the first dose of the study
drug
- Known central nervous system involvement by lymphoma
- Clinically significant cardiovascular disease
- History of stroke or intracranial hemorrhage within 6 months before first dose of
study drug
Note: Other protocol defined Inclusion/Exclusion criteria may apply.